Corrie Berk
Nurse Practitioner · San Antonio, TXNPI 1497299184
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Madrigal Pharmaceuticals at 41.5% of the total. 2025 is the largest year on record at $73,028, 7.6 times the $9,657 reported in 2021. Among nurse practitioner clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 376 payments — averaging $413.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$64K
- Gilead$58K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$19K
- Ipsen Biopharmaceuticals, Inc$9K
- AbbVie$3K
- Mallinckrodt Hospital Products Inc.$1K
- plus $737 from 7 others
What the payments were for
- Consulting fees$10,2057%
- Speaking & faculty fees$92,25959%
- Travel & lodging$42,42027%
- Food & beverage$10,5067%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 99 | $64,424 |
| Gilead | 130 | $58,310 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 93 | $18,696 |
| Ipsen Biopharmaceuticals, Inc | 19 | $8,646 |
| AbbVie | 18 | $3,382 |
| Mallinckrodt Hospital Products Inc. | 2 | $1,194 |
| Boston Scientific | 5 | $453 |
| Janssen Scientific Affairs, LLC | 1 | $101 |
| Orphalan Inc | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Intercept Pharmaceuticals, Inc. | 2 | $36 |
| AstraZeneca | 1 | $23 |
| Mirum Pharmaceuticals, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$63,468
- Epclusa$33,215
- XIFAXAN$19,515
- Livdelzi$16,768
- IQIRVO$7,452
- TRULANCE$5,058
- RELISTOR$3,463
- Mavyret$2,955
- TERLIVAZ$1,170
- RESMETIROM$123
- GENERAL VASCULAR INTERVENTION$121
- TheraSphere Y90 Glass Microspheres 10 GBq$106
- TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)$101
- Tremfya$101
How this compares
$155,390 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 11 | $37,177 |
| Ursodiol | 35 | $3,940 |
| Sirolimus | 12 | $2,762 |
| Lactulose | 80 | $2,367 |
| ConstuloseLactulose | 53 | $2,165 |
| Acamprosate Calcium | 12 | $1,483 |
| Tacrolimus | 16 | $1,207 |
| Spironolactone | 66 | $949 |
| EnuloseLactulose | 19 | $646 |
| Furosemide | 90 | $535 |
| Hydroxyzine Hcl | 17 | $285 |
| Carvedilol | 62 | $240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $18,696 | $37,17711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in San Antonio
- Sonja BruneSan Antonio$51K
- Laura GalvanSan Antonio$32K
- Eduardo GonzalezSan Antonio$32K
- Roberta RomeroSan Antonio$26K
- Christopher GarciaSan Antonio$21K
- Jennifer ZavalaSan Antonio$17K
- Amy RivasSan Antonio$17K
- Alexis WahlenSan Antonio$16K
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.